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Abstract: Despite the lifetimes that increased in breast cancers due to the the early screening programs and new therapeu-
tic strategies, many cases still are being lost due to the metastatic relapses. For this reason, new approaches such as the 
proteomic techniques have currently become the prime objectives of breast cancer researches. Various omic-based tech-
niques have been applied with increasing success to the molecular characterisation of breast tumours, which have resulted 
in a more detailed classification scheme and have produced clinical diagnostic tests that have been applied to both the 
prognosis and the prediction of outcome to the treatment. Implementation of the proteomics-based techniques is also seen 
as crucial if we are to develop a systems biology approach in the discovery of biomarkers of the early diagnosis, prognosis 
and prediction of the outcome of the breast cancer therapies. In this review, we discuss the studies that have been con-
ducted thus far, for the discovery of diagnostic, prognostic and predictive biomarkers, and evaluate the potential of the 
discriminating proteins identified in this research for clinical use as breast cancer biomarkers. 
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1. INTRODUCTION 
Breast cancer is the most commonly encountered cancer 
in our country, as it is in the world [1, 2]. Breast cancer oc-
curs in four stages. While the cases in the places where the 
preventive medicine is widespread and/or can benefit from 
the developed medical technologies, and receive diagnosis in 
the first or second stage, the others receive diagnosis in the 
third and fourth stages. Only half of the cancer cases that 
receive diagnosis are within the localized period [3].  
Although not withstanding promising progress has been 
made by the application of the screening programs and the 
systemic therapies in the breast cancer cases, there are still 
many patients dying following the metastatic relapse. This 
fact brings new approaches in breast cancer researches to the 
agenda. What this means in clinical terms is that under to-
day’s therapeutic conditions, these early diagnosed cases 
have approximately a nine times greater expectation of re-
maining healthy for 10 years compared to those of advanced 
periods [4]. 
Breast cancer is a complex disease which can gain a 
more invasive and resistant character by numerous molecular 
changes that bring about cell proliferation and genetic insta-
bility. This heterogenity creates different subgroups in mo-
lecular level and causes different clinical results and thera-
peutical responses. Studies that are done for the purpose of 
reaching better clinical results, have been focused on deter-  
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mining the molecular structures which are the causes of the 
disease, the cancer markers and the molecular structures that 
can constitute new therapeutical objectives, which can fol-
low up the early diagnosis of the disease, therapeutical re-
sponse and the relapses after the therapy by setting forth the 
stages of the disease and the differences that are peculiar to 
disease and person [5]. This approach, which requires the 
observation of the cellular changes simultaneously, has re-
flected in the clinical studies only by the developing tech-
nology, within the completion process of the genom analysis. 
The genom studies have enabled us to understand the mo-
lecular fundamentals of the diseases. However, rapidly 
changing cellular functions have clarified through proteome 
studies because the same genom may give rise to different 
proteome outputs [6]. While the term “proteome” was first 
used in 1994 and refers to the collection of proteins of one 
cell, tissue or organism, the “proteomic” refers to the studies 
related with all the biological activities of the proteome. In 
cancer researches, the protemoic technologies produce very 
valuable data, differentiating and describing functional and 
organisational medical pathways [7], determining the mo-
lecular structure which is the cause of the disease in tissue 
and biological liquids, the stages of the disease or the differ-
ences peculiar to the disease and the patient [8]. In recent 
years, the proteome studies that are done in various biologi-
cal samples have increased. Numerous preliminary studies 
are being performed on tumour tissue and biological fluids 
(serum, needle aspiration fluid, ductal lavage fluid and tu-
mour intercellular fluid) for the purpose of understanding the 
disease processes better in the breast cancer, too.  
In this review, the clinical applications of the proteomic 
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2. PROTEOMIC METHODS 
In clinical studies, certain methods have come into 
prominence in terms of its applicability in the field. The 
methods of determination of known proteins either multiply 
or as multiple samples simultaneously, form the basis of mi-
cro array techniques. In this field, micro arrays of tissues are 
used which measure a known protein sequence simultane-
ously in a large number of tumour tissue samples. The stud-
ies which started at the level of DNA, mRNA, were first 
used for immunohistochemistry at the protein level in 1998. 
None the less, there are about 1500 publications in the field 
of cancer. [TMA is so far the most used proteomic technique 
in oncology whith more than 4,600 publications in PubMed 
in November 2009 which involves in the terms of “tissue 
microarrays” and “cancer”]. 
The most important advantage of this method is its ability 
to evaluate a large number of samples under the same condi-
tions simultaneously, and have the ability to perform analy-
sis with both paraffin block and frozen tissue samples. It is 
also useful from the point of tissue archiving. In this area 
another technique which has just started to be used is the 
forward and reverse phase protein microarray method, which 
has made it possible to work with tissue lysates, interstitial 
fluids and serum samples. However, the limiting aspect in all 
these array methods is that, the analyses are limited to those 
performed with known antibodies [9].  
The methods which can define and measure large num-
bers of unknown proteins are the techniques based on mass 
spectrometric (MS). After a chemical or physical separation, 
a large number of protein markers defining the tumour phe-
notype may be measured. Mass spectrometry based tech-
niques require substantial sample preparation prior to analy-
sis. The immune affinity, 2- dimensional gel electrophoresis 
(2DE), and free flow electrophoresis (FFE) are the most 
widely used methods [10]. In the traditional method of 2DE 
proteins are separated from a complex mixture according to 
electrical charge and dimensional differences. The advantage 
of this method is that large numbers (3.000-10.000) of pro-
teins can be separated visually. The technique was first de-
scribed by O’Farrel in 1975 [11]. The first 2-dimensional gel 
based proteomic database was created in 1981 [12]. The 
problems of repeatability and standardisation associated with 
the method were overcome with the use of the Immobilised 
pH gradient (IPG) [13]. The development of the differential 
in gel electrophoresis (DIGE) technique, in which proteins 
from different sources are marked with fluorescent dyes, 
separated with 2DE and defined by MS, increased the use of 
the method especially in cancer research. However, difficul-
ties continue with the visualisation of proteins in very small 
amounts or of very large or very small dimensions. It is still 
widely used because it makes functional proteomic and anti-
body studies possible, and because of its superiority in the 
definition of unknown proteins [14]. In spite of this, methods 
of analysis which do not rely on a gel substrate are used 
more frequently in clinical studies. Liquid chromatography 
(two-dimenisonal liquid-phase separation together with IEF) 
and its joint use with isotope-coded affinity tags (ICAT) 
providing sample tagging at source, the possibility of multi-
dimensional protein analysis afforded by multidimensional 
protein identification technology (MudPIT) HPLC-cation 
exchange and reverse phase partnered with (MS/MS), pro-
vides the required quick and easy sample preparation for 
clinical samples [15-18].  
In Mass spectroscopy which has begun to be used in re-
cent years, the analysis of complex protein samples is per-
formed by the determination of the mass/charge ratio (m/z) 
and the number of ions for each m/z value of a pressurised 
gas phase ion mixture. A mass spectrometer consists of an 
ionisation source, a mass analyser and a detector. In protein 
biochemistry two ionisation techniques are used predomi-
nantly: Matrix-assisted laser desorption ionisation (MALDI) 
for the analysis of simple peptide structures, and electrospray 
ionisation (ESI) for more complex samples. However, be-
cause it enables analysis of more complex samples, surface 
enhanced laser desorption ionisation (SELDI) a development 
of the MALDI technique, is widely used especially in cancer 
proteomics. In this method protein wafers with a choice of 
different surfaces are used for protein purification, analysis 
and molecular reactions. 
Four types of mass analysers are used commonly in pro-
teomic studies: ion trap, time of flight (TOF), quadrupole, 
and Fourier transform ion cyclotron (FT-MS). For analysis 
of the mass spectrum, statistical and bioinformatics tools are 
needed,some commercially available examples of them are 
Proteome, Quest, Propek, Bamf, and Biomarker Wizard [19, 
20]. 
In literature, attention is drawn to two important topics 
regarding SELDI-TOF-MS analyses. The first of these is 
providing a selection process prior to data analysis of the 
spectra which has poor quality and the lack of analytical va-
lidity as well as the quality control procedures that are per-
formed for this purpose. This procedure will reduce noise in 
the proteomic data, and will be reflected as lower variability 
in diagnostic validity [21]. Another problem discussed is in 
terms of diagnostic validity. The protein pattern data with 
SELDI-TOF MS are obtained with small sample size case 
groups relative to the large amount of data. However, in se-
lecting the target, the small group which is going to be stud-
ied, it must be selected with very definite criteria and as few 
variables as possible. 
In regards to the target peaks determined, these must be 
validated with a broader case group and bioinformatic tools 
must be used, effectively [22]. The plentiful candidate pro-
teins available consist mostly of proteins which are the re-
sponse of the acute phase, and cancer specific proteins have 
not yet gained clinical validity. The main advantages and 
disadvantages of each technique have been outlined in Table 
1. 
2.1. Breast Cancer Clinical Applications 
2.1.1. Tissue Microarray Applications 
The first protein array study in breast cancer was pub-
lished by Kononen in 1998 [23]. This technique has been 
used to research the clinical significance of a small number 
of target proteins, frequently in large series of specimens. To 
date, (2009) there are 843 pubmed sourced publications on 
the use of tissue microarray applications for breast cancer 
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2.1.2. Use for Diagnostic Purposes 
2.1.2.1. Molecular Level Definition Of Previously Known 
Diagnostic Classes 
The genetic classification in breast cancer has been de-
fined as sporadic (approximately 90% of cases) and heredi-
tary (approximately 10% of cases) [25]. Afterwards, it has 
been differentiated according to their mutation conveyance 
in the BRCA1 and BRCA2 genes. This genotypic classifica-
tion has been confirmed by Hedenfalk et al. [24] using a 
DNA microarray with a series of genes also containing the 
CCND1 gene. Palacios et al. [26] have confirmed this mo-
lecular classification with a study (CCND1, hormone recep-
tors, p53, ERBB2, cell cycle regulators, apoptosis and basal 
cell indicator proteins) at the protein level covering 37 pro-
teins. BRCA2 cancers have been found to be related to cycle 
regulators, D type cyclines (D1, D3), and CDK4. However, 
it has also been reported that in BRCA1 cancers, the 
ER/ERBB2 negativity, rapid proliferation, and basal pheno-
type is widespread [26, 27]. In the recognition of the mole-
cules of lobular and ductal cancers, the use of the proteins 
EMP1, DVL1, DDR1 and PRKC1 is recommended together 
with E-cadherin [28]. 
Medullar breast carcinoma is a rare cancer but is known 
to have a poor prognosis. The persistence of the difficulties 
with morphological diagnosis has required the molecular 
definition. A definition using a series containing 18 proteins 
[29] has been confirmed by Bertucci et al. with their study 
using a DNA microarray [30]. At the protein level, an in-
crease in p-cadherin, M1B1/Ki67, negative ERBB2, and 
positive p53 have been linked with medullar breast carci-
noma. 
In the studies which bring clarity to advances in breast 
oncogenesis, it has been observed that the role of the protein 
14-3-3, described as a tumour suppressor in previous publi-
cations, is less than had been supposed [31], and the lymph 
node metastasis has been linked to ERBB2 status [32].  
Table 1. The Main Advantages and Disadvantages of Proteomic Techniques 
Technique Advantages  Disadvantages 
Protein Microarray  High throughput  
Specific for protein interactions with many class of molecules 
Detects only known proteins 
Antibody specificity 
Difficult to have protein in native conformation 
2D-Page  Hundreds to thousands of polypeptides can be analyzed in a single 
run 
The proteins can be separated in pure form 
Polypeptides can also be probed with antibodies and tested for 
post-translational modifications. 
Used to study differential expression of proteins between cell 
types 
Semi-quantitative measurement of protein expression  
MS identifies peptides originating mainly from a single protein; 
identification of the protein more direct 
Manual work required 
Problematic analysis of very low- or very high-Mr 
proteins 
Salt ions could interfere with protein separation 
Suppression of signal by high abundant proteins 
Limited reproducibility 
Smaller dynamic range than some other separation 
methods 
Mass Spectroscopy  High sensitivity 
Automation is developed,  
High throughput experiments 
Suitable for coupling with other methods 
MS identify peptides; final software analysis groups 
peptides belonging to a protein; identification of 
proteins less direct  
Manual work is required 
Low protein identification rate (<10%) 
No match with experimentally measured Mr and pH 
 MALDI-TOF-MS 
“Matrix-assisted laser desorp-
tion ionization” 
High sensitivity 
Relatively quick analysis  
Requires relatively pure samples  
More ambiguity in identifications due to lack of 
true sequence dependence of 
Exact, or high homology protein sequence must be 
present in database 
SELDI-TOF-MS 
“Surface-enhance laser 
desorption ionization” 
High sensitivity 
High throughput  
Suitable for clinical samples 
Automation is developed, a little manual work is required 
Requires validation for clinical diagnosis 
Relatively expensive  
A selection process prior to data analysis of the 
spectra which has poor quality 
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Another cancer, whose diagnosis involves difficulty, is 
the inflammatory breast cancer. Very few things are known 
concerning the molecular structure of this cancer which is 
rare but can frequently be fatal. In proteomic studies, with a 
protein signature defined by an increase in E-cadherin,   
ER(-), MIB1(+), MUC1(cytoplasmic staining) and 
ERBB2(+), 91% of the cancer can been defined [33-35]. 
2.1.2.2. Discrimination of New Subgroups in Breast Can-
cer and Definition at the Molecular Level 
In the general hierarchical classification of breast cancer 
there are many studies defining the molecular structures of 
the ER positive and ER negative groups. With the addition 
of proteins related to cell type and signal pathway to these 
defined structures, five molecular subtypes of ER positive 
tumours have been distinguished. The sub types defined at 
the proteomic level, luminal  A, luminal  B, basal, overex-
pressing ERBB2, and normal, have been confirmed by clini-
cal data [36-39]. 
Together with the pathologic characteristics of breast 
cancer, in studies which are conducted on large sample series 
defining the molecular sub types, as many as 97 proteins 
have been determined, including ER, PR, ERBB2, p53, 
CK5/6, CK8/18, cyclin  E, Ki67, BCL2, cyclin  D1, and 
E-cadherin [40-42]. In the evaluations performed in conjunc-
tion with survival periods, 26 proteins were selected for fol-
low up and the 5 year survival period was determined to be 
80%. In addition to these proteins, with an investigation per-
formed on four separate groups [metabolic (ER status), func-
tional (proliferation, mitosis, differentiation)] protein pat-
terns and survival expectations were classified as 3 different 
sub groups [A1, A2, B] [43]. These studies revealed more 
than ten protein markers that may distinguish disease sub-
groups clinically and biologically more reliably than the 
prognostic markers were being used [44, 45]. 
A defined molecular classification can be performed for 
luminal and ERBB2 positive tumours with proteomic stud-
ies, whether for diagnostic or therapeutic purposes. How-
ever, a valid diagnostic and therapeutic molecular definition 
for the basal group has not yet been obtained. In a small 
number of studies ER, ERBB2 negativity, CK5, CK5/6, 
EGFR positivity has been proposed as a diagnostic marker 
for a small sample group. This molecular pattern has been 
evaluated together with survival in a larger sample group 
[46-49]. 
2.1.2.3. Proteomic Microarray in Breast Cancer Prognosis 
The majority of the studies that are done in this field, 
have been realized and oriented towards scanning only one 
protein during the cancer follow up, in large sample groups. 
In studies performed with multiple protein patterns, AIB1, 
MUC1, MUC3, COX2, TERT, EpCAM/TACSTD1, EPIL, 
in the basal group crystalline -B, cytokeratin 5 and 17, an-
nexin A8, have been linked with poor clinical trend, whereas 
STAT5, BCL2, in the ER-luminal group GATA3, in the 
ERBB2 group GATA4, Ki67, ERBB2, have been linked 
with favourable clinical trend [50-62]. 
It was reported by Bertucci et al. [63] that a 21 protein 
pattern defined in a 5 year metastasis prediction of survival 
study concluded more favourably than the current standards, 
and in an independent study 9 of these proteins were ap-
proved [64, 65]. 
2.1.2.4. Tissue Microarray Studies in the Prediction of 
Therapeutic Response 
There are very few tissue microarray studies for thera-
peutic response in breast cancer. Simon et al. [66] proposed 
the use of KIT mutations for imatinib, Linke et al. [67] pro-
posed the use of BCL2, ERBB2, MYC, TP53 proteins for 
tamoxifen and Rouzier et al. [68] proposed the use of TAU 
protein for paklitaksel. 
Imatinib therapy’s target KIT expression was not associ-
ated with survival. Unlike fragile histidine triad, tyrosine-
phosphorylated STAT5, or BCL2 proteins correlated with 
favorable clinical outcome. BCL2 was the only independent 
prognostic factor. BCL2 impact was then confirmed in an 
independent series of 1,961 tumors [64]. 
The favorable prognostic impact of GATA3 expression 
was correlated at the protein level [59]. 
Genes included in the basal cluster were also tested, and 
their negative prognostic role was confirmed in several hun-
dreds of tumors; crystallin alpha B, cytokeratins 5, 17 and 
annexin A8. Using DNA microarrays identified a gene ex-
pression signature correlated with ERBB2 status [63]. 
The protein level the positive correlation of GATA4 and 
Ki67 with ERBB2. Rouzier et al. [68] confirmed on 122 
independent tumors the correlation between low expression 
of the microtubule-associated protein TAU and sensitivity to 
neoadjuvant paclitaxel identified by gene profiling.  
ER status, the 21-protein pattern was the strongest inde-
pendent predictor of clinical outcome. Supervised analysis 
was applied to nine proteins of 21 proteins pattern in stage I 
to III breast cancers treated with adjuvant tamoxifen [67]. 
2.2. Mass Spectroscopy Applications 
In the years between January 1995 and November 2009 a 
total of 1191 articles were published concerning the applica-
tion of mass spectrometry in breast cancer. Only 20 of these 
studies involved protein definition [69]. 
2.2.1. Use of Mass Spectroscopy for Diagnostic Purposes 
To establish and define protein patterns in the clinical 
meaning, elegant studies have been conducted, mostly with 
the MALDI/SELDI methods in numerous biological sources 
such as serum, plasma, tissue interstitial fluid, thin needle 
aspiration fluid, ductal lavage fluid, and saliva. 
Despite being a less commonly chosen source in clinical 
studies due to the difficulty in tissue sampling, because of 
the diagnostic biomarkers peculiar to cancer, tumour tissue is 
a very good source. However, due to some reasons such as 
the difference in protein content validation of the compounds 
for breast cancer has not been obtained, yet. Umar et al. [70] 
have reported 9 tryptic peptides, which was determined as 
specific to breast cancer but was not defined structurally, as a 
diagnostic biomarker. Sanders et al. [71] defined S100-A6 
protein, as a growth factor in breast tumour, for being an 
increasing marker, and the proteins S100-A8 and ubiquitin 
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As is the case for all forms of cancer, serum and plasma 
are the preferred sources in biomarker studies that are per-
formed for breast cancer because; they produce a rather ac-
tive response to the physiological and pathological processes 
of the human body. This is a rich source of information on 
proteins. Together with the proteins secreted by the tumour, 
this also includes in the proteins of the normal tissue and 
plasma which is destroyed by proteases specific to the tu-
mour, and those proteins causing a general response or a 
response local to the tumour. Despite the difficulty arising 
from this complex structure, methods ease in sampling and 
repetability makes it extremely suitable [72, 73]. 
In serum and plasma sourced studies performed using the 
MALDI-TOF-MS and SELDI-TOF-MS methods, mostly 
without having a structural definition, protein patterns have 
been proposed for purposes of diagnosis and classification in 
breast cancer. Becker et al. [74] in the definition of cancers 
involving BRCA-1 mutation, Laronga et al. [75] and Vlahou 
et al. [76] have proposed the use of protein patterns for diag-
nosis and classification. However, the structural definitions 
of proteins have not been made in these studies, and their 
validity has not yet been tested in an independent case group. 
In the case of seven protein patterns proposed in a diagnosis 
and classification which is carried out by Belluco et al. [77] 
although they have not been structurally defined, their valid-
ity has been tested in an independent case group and they 
have been presented as candidate proteins. 
Three protein pattern biomarkers have been determined 
by Li et al. in breast cancer, one reducing (4.3 kDa), and two 
increasing (8.1 and 8.9 kDa) and in subsequent studies, their 
structural definitions have been determined respectively as 
ITIH4 (inter-alpha-tyripsin inhibitor heavy chain H4), 
C3adesArg8 (C3a des-arginine-C terminal truncated peptide), 
and C3adesArg (C3a des-arginine) and these have been re-
peated in independent case groups [78, 79]. 
However, in later publications related to these biomark-
ers; the increase in cancer cases of the 8.1kDa marker has 
not been found to be meaningful [80-83], and the 8.9kDa 
marker is reported to have decreased in metastatic recur-
rences [84]. As for the ITIH4 (4.3kDa) fragment, in studies 
performed by Song et al. [85], Villenueva et al. [86] and 
Fung et al. [87] it has been found to increase in cancer cases. 
Thus in the diagnosis of breast cancer the value of these 3 
biomarkers proposed by Li et al. is still in dispute. 
As ITIH4, the use of markers such as fibrinopeptide A, 
fibrinogen alpha, C3f, C4a, apolipoprotein A-IV, bradykinin, 
factor XIII, and transthyretin, reflecting the clotting status in 
the blood of cancer sufferers, are suggested for the diagnos-
tic and classification purposes. The serum and plasma levels 
of these markers imply variations peculiar to the matrix [87, 
88]. 
A very few of the studies made on ductal lavage fluid and 
needle aspiration fluid, traditionally used for cytological 
evaluations, have a normalisation based on protein content 
been performed. For this reason, they have revealed a broad 
distribution. Sauther et al. [89, 90] found 3 protein peaks, 
one of them being the haemoglobin beta chain isoform. In 
another study of very low sample number, an increase in 
neutrophile peptides has been demonstrated [91]. 
A matrix has been constructed for breast cancer biomark-
ers in saliva secretions. It was found that soluble c-erbB-2 
and CA 15.3, and 5 proteins of high molecular weight (18, 
113, 170, 228, and 287 km/z), as yet without a structural 
definition, increased in cancer cases [92].  
2.2.1.1. Use of Mass Spectroscopy in Follow up Of Breast 
Cancer 
Proteomic studies in the follow up of breast cancer, to-
gether with use for diagnostic purposes, are still limited in 
number. A pattern defined as 40 protein signatures proposed 
by Goncalves et al. [93], predicted the clinical results of 83% 
of patients, correctly. This pattern, which includes haptoglo-
bin alpha-1, complement  C3a, transferin, and apolipro-
tein A-I and C-I, has not yet been confirmed by an independ-
ent group.  
In tissue lysates, an increase in ubiquitin and a decrease 
in ferritin light chain have been linked with good clinical 
progress [94], and have been confirmed in independent 
groups and cell series [95-97]. Studies performed on cerebral 
and spinal cord fluid are important from the aspect of metas-
tases within the central nervous system. Central nervous sys-
tem metastases have been defined with 77% accuracy using 
numerous peptides such as apoliprotein  A-1 and E, hapto-
globulin, transferin, transthyretin, prostaglandin  D2 syn-
thase, and haemopexin [98, 99]. 
The clinical progress of cancer is predicted according to 
TNM classification. In microarray based studies 5 different 
molecular type subgroups have been determined (luminal A 
and B, ERBB2 overexpressing, basal-like, and normal-like), 
and confirmed with tissue protein arrays [68,100-102]. 
Heat shock protein (HSP) 27  and  annexin V  increase  in 
luminal A type cancers. It has been determined that S100-A9 
increases in basal type cancers and it has been linked with 
poor clinical progress [95]. 
2.2.1.2. Use of Mass Spectroscopy in Prediction of Thera-
peutic Response 
The correct prediction of chemo-sensitivity in cancer 
therapy, whilst offering protection from toxic side effects, 
will cause a reduction in the use of ineffective medication 
and improved clinical results. For the determination of bio-
markers which will provide prediction of therapeutic re-
sponse and follow up of therapy, in the studies performed on 
drug sensitive and drug resistant (doxorubicin and paclitaxel) 
breast cancer cells with SELDI-TOF-MS, a large number of 
structurally undefined protein peaks have been proposed. 
Dowling et al. [103], proposed the use of transferrin frag-
ments, linked with poor clinical progress, for the prediction 
of paclitaxel resistance. In treatments stimulating apoptosis, 
a decrease in ubiquitin and S100-A6 and abnormal expres-
sion in breast cancer tissue was found [94,104]. 
However, the results of these studies have not yet been 
transferred to clinical samples. In the limited number of in 
vivo studies performed in this field, it was determined that 
the kininogen and apolipoprotein A-II decreased in the shock 
table caused by docetaxel [105], and the structurally unde-
fined SELDI peak, determined as 2790 m/z, increased mark-
edly after paclitaxel infusion administered as an adjuvant 
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However, it has not yet been possible to define a proteo-
mic predictive marker to predict either therapeutic response 
or the responses to cytotoxic treatment, whether of micro-
metastatic carcinomas or of the whole body. 
3. CONCLUSION 
The proteomic methods are being used in breast cancer 
researches and in recent years at an increasing rate. In the 
literature (pubmed) between the years 1996 and 2009, there 
are about 556 publications related to breast cancer and pro-
teomics. In these studies examined by the code updating 
committee of ASCO (the American Society of Clinical On-
cology) which regulates the use of tumour markers in breast 
cancer, many candidate proteins, found [107].  
In serum, aspiration fluid (NAF), tumour tissue and in-
tercellular fluid (TIF), were evaluated as proteomic indica-
tors showing promise for clinical use. However, it was also 
proposed that these researches should be repeated with pro-
spective studies to be performed with well-defined larger 
sampling groups, in different populations and with different 
analytical methods. In clinical trials, there are about 40 stud-
ies in progress relating to breast cancer and proteomics. At 
present, none of the proteomic profiling techniques has been 
validated sufficiently for use in patient care [107-109]. 
In the definition of cancer indicators, the proteomic tech-
nologies are producing very valuable data, differentiating 
and defining functional and regulatory pathways, determin-
ing the structure of disease causing molecules in tissue and 
biologic fluids, and manifest the disease stages or differences 
specific to the disease or to the individual. 
This data will be reflected to the clinic in the form of the 
definition of effective markers providing early disease diag-
nosis, and the detection of response to treatment and of post 
treatment relapse. 
In spite of all these encouraging developments, the usage 
of the proteomic markers for diagnostic purposes still re-
quires a series of validation studies. As a consequence of all 
these studies, the use in conjunction with other diagnostic 
procedures (mammography, immunoassay, ultrasound, fae-
cal occult blood test, etc.), early diagnosis, and also the fol-
low up of responses to treatment may become important. 
In conclusion, a proteomic marker valid for clinical use 
has not yet been defined in breast cancer [107]. However, the 
proteomic studies, which gained pace with the founding in 
2001 of the international Human Proteome Organisation 
(HUPO), have shown promising results from the point of 
view of early breast cancer diagnosis, follow up and thera-
peutic predictive markers. 
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